Year Founded
2003
Ownership
Private
Employees
~5000
Therapeutic Areas
EndocrinologyInfectious Diseases
Stage
Commercial
Modalities
PeptidesOligonucleotide therapeuticsSmall moleculePeptide-drug conjugate (PDC)Peptides

Sinopep General Information

Leading API manufacturer for major peptides including semaglutide, tirzepatide, and liraglutide. Exclusive API supplier for Albuvirtide and Lanreotide 505b2.

Contact Information

Website
Primary Industry
[ "Biotech", "CDMO", "Other" ]
Corporate Office
Lianyungang, Jiangsu
China

Drug Pipeline

semaglutide
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Sinopep's pipeline data

Book a demo

Key Partnerships

Spraying Systems Co., Multiple undisclosed pharmaceutical companies

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Sinopep Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Sinopep's complete valuation and funding history, request access »